Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 301 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Reflux Disease, Gastro-Esophageal Clear all
Completed Phase 4 Interventional

Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

NCT00251732
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Standard dose (once daily) PPI plus low-dose antidepressant, Double dose PPI plus evening placebo, Rabeprazole , placebo, placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 10, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

NCT05195528
View directory record Official record
Conditions
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
108
States / cities
Athens, Alabama • Cullman, Alabama • Huntsville, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 10, 2026, 12:56 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

NCT07752407
View directory record Official record
Conditions
Symptomatic Non-erosive Gastroesophageal Reflux Disease
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Mentor, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 10, 2026, 12:56 AM EDT
Completed Not applicable Interventional

Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease

NCT04491734
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
maltosyl-isomalto-oligosaccharides (MIMO)
Dietary Supplement
Lead sponsor
ISOThrive Inc.
Industry
Eligibility
25 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 10, 2026, 12:56 AM EDT
Terminated Phase 4 Interventional Results available

PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects

NCT02401035
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
IV pantoprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Year to 16 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Dallas, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 10, 2026, 12:56 AM EDT
Completed Phase 4 Interventional Results available

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

NCT00693225
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Omeprazole/sodium bicarbonate
Drug
Lead sponsor
Yvonne Romero
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Oct 10, 2026, 12:56 AM EDT
Terminated Not applicable Interventional

Domperidone for Relief of Gastrointestinal Disorders

NCT00761254
View directory record Official record
Conditions
Gastroparesis, GERD, Esophagitis, Dyspepsia, Chronic Idiopathic Constipation, Nausea, Vomiting
Interventions
Domperidone
Drug
Lead sponsor
Carle Physician Group
Individual
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 10, 2026, 12:56 AM EDT
Completed Not applicable Interventional Results available

Response to Supplement and Placebo in GERD

NCT01915173
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Heartburn, Dyspepsia
Interventions
Supplement, Placebo, Expanded Interview, Standard Interview
Drug · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 10, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

Phase 3/Safety & Efficacy of Esomeprazole in Infants

NCT00468559
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Month to 11 Months
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 10, 2026, 12:56 AM EDT
Completed No phase listed Observational

Pharmacogenetic Testing in Children With Persistent Gastroesophageal Reflux Disease

NCT03005080
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 10, 2026, 12:56 AM EDT
Recruiting Not applicable Interventional

Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia

NCT06534359
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Gastroesophageal Reflux
Interventions
Transpyloric tube feeding, Gastric tube feeding
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 12 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 10, 2026, 12:56 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry

NCT00574327
View directory record Official record
Conditions
Barrett's Esophagus, Gastroesophageal Reflux Disease, Esophageal Adenocarcinoma
Interventions
Not listed
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2029
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 10, 2026, 12:56 AM EDT
Enrolling by invitation No phase listed Observational

Assessment of Esophageal Epithelium Integrity With Use of a Novel Mucosal Impedance Device

NCT03103789
View directory record Official record
Conditions
Gastro Esophageal Reflux
Interventions
single catheter mucosal impedance testing, balloon assembly mucosal impedance testing
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
75 participants
Timeline
2014 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 10, 2026, 12:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Survey Study on Barrett's Esophagus Screening

NCT04408105
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Barrett's Esophagus, Esophagus Adenocarcinoma
Interventions
Primary Care Provider Survey, Gastroenterologist Survey, Patient Survey
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
725 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
7
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 10, 2026, 12:56 AM EDT
Withdrawn Not applicable Interventional

A Study to Evaluate the Role of Alternative Medicine in Difficult to Treat GERD Patients

NCT00591877
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Acupuncture, Sham Acupuncture, Yoga
Procedure · Other
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 10, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT01472939
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI, Placebo + PPI
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 10, 2026, 12:56 AM EDT
Withdrawn Not applicable Interventional

Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)

NCT02039869
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Non Erosive Reflux Disease, Dyspepsia
Interventions
Confocal endomicroscopy, Proton pump inhibitor, Sucralfate
Device · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Kenner, Louisiana • Charleston, South Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 10, 2026, 12:56 AM EDT
Withdrawn Phase 1 Interventional

Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months

NCT02442752
View directory record Official record
Conditions
Pediatric Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Month to 11 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Los Angeles, California • Louisville, Kentucky • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 10, 2026, 12:56 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.

NCT00674245
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Pantoprazole, placebo
Drug
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 10, 2026, 12:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Can We Predict Who Has Gastroesophageal Reflux Disease (GERD)?

NCT01204931
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 10, 2026, 12:56 AM EDT
Recruiting Phase 4 Interventional

Gastrointestinal Dysmotility on Aspiration Risk

NCT05455359
View directory record Official record
Conditions
Esophageal Motility Disorders, Gastric Motor Dysfunction, Aspiration Pneumonia, Gastro Esophageal Reflux
Interventions
Prucalopride, Famotidine
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 10, 2026, 12:56 AM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Oct 10, 2026, 12:56 AM EDT
Completed Not applicable Interventional Results available

Clinical Studies on Bile Acids in Barrett's Esophagus

NCT00858858
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Ursodeoxycholic Acid
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 10, 2026, 12:56 AM EDT
Completed No phase listed Observational

RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol

NCT01406210
View directory record Official record
Conditions
Reflux, Gastroesophageal Reflux Disease (GERD)
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
16 Years and older
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 10, 2026, 12:56 AM EDT